Search | IOVS | ARVO Journals

Showing 1 – 20 of 111

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2022

Commercially available, unmodified Octopus perimeters can characterize rod-photoreceptor function in two-color dark-adapted perimetry

Lesley Everett; Austin David Igelman; Jason Changbum Park; Robert Alexander Hyde; J Jason McAnany; Paul Yang; Mark E Pennesi

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):2246 – F0454. doi:

ARVO Annual Meeting Abstract June 2022

Findings on visual photosensitivity in two phase 1/2 clinical trials of subretinal gene therapy with AGTC-401 and AGTC-402 for CNGB3 and CNGA3 achromatopsia

Rachel M Huckfeldt; Jason Comander; Mark E Pennesi; Paul Yang; Andreas Lauer; Robert Sisk; Edward Averbukh; Eyal Banin; Ninel Z Gregori; Janet L Davis; Byron L Lam; Christine Nichols Kay; Jessica Ijams Wolfing Morgan; Joseph Carroll; Bright Senyo Ashimatey; Matthew Feinsod

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):450. doi:

ARVO Annual Meeting Abstract June 2022

Characterizing the refractive error during the first 2 decades of life in patients with congenital stationary night blindness

Austin David Igelman; Thomas Khuu; Alaa Tayyib; Milda Reith; Birgit Lorenz; Erin O'Neil; Shaden Yassin; Andrew Stephenson; Emily Krauss; Ogul Uner; Justin Grassmeyer; Paul Yang; Lorri Wilson; Douglas Fredrick; Mark E Pennesi

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):253 – A0107. doi:

ARVO Annual Meeting Abstract June 2022

Characterization of refractive error progression in patients with blue cone monochromacy

Thomas Huynh Khuu; Austin David Igelman; Paul Yang; Mark E Pennesi

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1720 – F0038. doi:

ARVO Annual Meeting Abstract June 2022

Exploratory Safety Profile of EDIT-101, a First-in-Human in vivo CRISPR Gene Editing Therapy for CEP290 -related Retinal Degeneration

Michael C Jaskolka; Saleh El-Husayni; Brian Duke; Amanda Erlwein; Rene Myers; Mark E Pennesi; Eric A Pierce; Lisa A. Michaels; Mark Shearman; Kate Zhang; Swati Mukherjee

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):2836 – A0352. doi:

ARVO Annual Meeting Abstract June 2022

Interim Safety Results in Two Phase 1/2 Open-label, Dose-escalation Clinical Trials of Subretinal Gene Therapy with AGTC-401 (rAAV2tYF-PR1.7-hCNGB3) and AGTC-402 (rAAV2tYF-PR1.7-hCNGA3) in Subjects with Achromatopsia (ACHM)

Alessandro Iannaccone; Mark E Pennesi; Paul Yang; Andreas Lauer; Robert Sisk; Ninel Z Gregori; Janet L Davis; Byron L Lam; Christine Nichols Kay; Mauro Goldbaum; Bright Senyo Ashimatey; Feng Zhu; Matthew Feinsod; Lejla Vajzovic

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):2829 – A0345. doi:

ARVO Annual Meeting Abstract June 2022

18 Month Analysis of Macular Structure using Optical Coherence Tomography (OCT) from a Phase 1/2 Clinical Study of Subretinal Gene Therapy Drug AGTC-501 for X-Linked Retinitis Pigmentosa

Paul Yang; Andreas Lauer; Mark E Pennesi; David G Birch; Rand Spencer; Robert Sisk; Alessandro Iannaccone; Matthew Feinsod; Mauro Goldbaum

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):4399 – F0078. doi:

ARVO Annual Meeting Abstract June 2022

Visual acuity and full-field stimulus thresholds (FST) over 2 years in the RUSH2A study: annual rates of change from mixed effects modeling

Peiyao Cheng; David G Birch; Jacque L Duncan; Frederick L Ferris; Maureen G Maguire; Allison R. Ayala; Janet K Cheetham; Todd Durham; Abigail T Fahim; Rachel M Huckfeldt; Michel Michaelides; Mark E Pennesi; Jose Alain Sahel; Katarina Stingl; Ajoy Vincent; Christina Y Weng

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):4480 – F0267. doi:

Retina March 2022

The RUSH2A Study: Dark-Adapted Visual Fields in Patients With Retinal Degeneration Associated With Biallelic Variants in the USH2A Gene

PDF

David G. Birch; Lassana Samarakoon; Michele Melia; Jacque L. Duncan; Allison R. Ayala; Isabelle Audo; Janet K. Cheetham; Todd A. Durham; Alessandro Iannaccone; Mark E. Pennesi; Katarina Stingl; for the Foundation Fighting Blindness Consortium Investigator Group
TAGS: genes, retinal degeneration, rod photoreceptors, visual fields, illness length
Invest. Ophthalmol. Vis. Sci.. 2022; 63(3):17. doi: https://doi.org/10.1167/iovs.63.3.17

Articles December 2021

Effect of Pharmacological Pupil Dilation on Dark-Adapted Perimetric Sensitivity in Healthy Subjects Using an Octopus 900 Perimeter

PDF

Austin D. Igelman; Cristy Ku; Sam Mershon; Mariana Matioli da Palma; J. Jason McAnany; Robert A. Hyde; Jason C. Park; Paul Yang; Mark E. Pennesi
TAGS: color, dilatation, pathologic, mydriasis, perimetry, pharmacology, pupil dilation, octopus
Trans. Vis. Sci. Tech.. 2021; 10(14):18. doi: https://doi.org/10.1167/tvst.10.14.18

Genetics June 2021

Characterization of the Spectrum of Ophthalmic Changes in Patients With Alagille Syndrome

PDF

Mariana Matioli da Palma; Austin D. Igelman; Cristy Ku; Amanda Burr; Jia Yue You; Emily M. Place; Nan-Kai Wang; Jin Kyun Oh; Kari E. Branham; Xinxin Zhang; Jeeyun Ahn; Michael B. Gorin; Byron L. Lam; Cecinio C. Ronquillo; Paul S. Bernstein; Aaron Nagiel; Rachel Huckfeldt; Michelle T. Cabrera; John P. Kelly; Benjamin Bakall; Alessandro Iannaccone; Robert B. Hufnagel; Wadih M. Zein; Robert K. Koenekoop; David G. Birch; Paul Yang; Abigail T. Fahim; Mark E. Pennesi
TAGS: arteriohepatic dysplasia, eye
Invest. Ophthalmol. Vis. Sci.. 2021; 62(7):27. doi: https://doi.org/10.1167/iovs.62.7.27

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2021

NIGHT study: natural progression of choroideremia

Byron L Lam; Robert E MacLaren; M. Dominik Fischer; Frank G Holz; Mark E Pennesi; David G Birch; Eeva-Marja Sankila; Isabelleanne Meunier; Kimberly E Stepien; Juliana M.F. Sallum; Cindy Lu; Jiajun Liu; Dan Yoon

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):34. doi:

ARVO Annual Meeting Abstract June 2021

Effect of pupil dilation on dark adapted perimetry using an Octopus 900 perimeter

Austin Igelman; Cristy Ann Ku; Mariana Matioli da Palma; Paul Yang; Mark E Pennesi

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):499. doi:

ARVO Annual Meeting Abstract June 2021

Patient-reported visual functioning in persons with bi-allelic USH2A variants

Elise Heon; B. Michele Melia; Laura E Bocchino; Jacque L Duncan; Allison Ayala; Chris Bradley; Isabelle Audo; Janet K Cheetham; Gislin Dagnelie; Todd Durham; Carel Hoyng; Nieraj Jain; Thiran Jayasundera; Mark E Pennesi; Christina Y Weng

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):3541. doi:

ARVO Annual Meeting Abstract June 2021

Twelve-month Findings from Two Phase 1/2 Clinical Studies of Subretinal Gene Therapy Drugs for Achromatopsia

Mark E Pennesi; Paul Yang; Andreas Lauer; Robert A Sisk; Jason M Comander; Rachel M. Huckfeldt; Edward Averbuhk; Eyal Banin; Ninel Gregori; Janet L Davis; Byron L Lam; Christine Kay; Erin Leone; Deanine Halliman; Nnenna Ihekoromadu; Matthew Feinsod

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):3321. doi:

ARVO Annual Meeting Abstract June 2021

Treatment outcomes in 11 patients with RPE65- retinopathy receiving voritegene neparvovec-rzyl

Cristy Ann Ku; Mariana Matioli da Palma; Austin Igelman; Andreas Lauer; Steven Bailey; Jacque L Duncan; Paul Yang; Mark E Pennesi

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):3320. doi:

ARVO Annual Meeting Abstract June 2021

Dark-adapted visual fields (DAVF) in patients with two disease-causing variants in USH2A

David G Birch; Lassana Samarakoon; Laura E Bocchino; B. Michele Melia; Jacque L Duncan; Allison Ayala; Isabelle Audo; Janet K Cheetham; Todd Durham; Alessandro Iannaccone; Mark E Pennesi; Katarina Stingl

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):3241. doi:

ARVO Annual Meeting Abstract June 2021

Phenotypic and genotypic spectrum of HGSNAT-related retinopathy

Mariana Matioli da Palma; Austin D. Igelman; Amanda Burr; Cristy Ann Ku; Paul Yang; Juliana M.F. Sallum; Mark E Pennesi

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):3225. doi:

ARVO Annual Meeting Abstract June 2021

Six Month Findings from a Phase 1/2 Clinical Study of Subretinal Gene Therapy Drug AGTC-501 for X-Linked Retinitis Pigmentosa Show Clinically Meaningful Improvement in Macular Sensitivity

Paul Yang; Andreas Lauer; Mark E Pennesi; David G Birch; rand spencer; Robert A Sisk; Alessandro Iannaccone; Erin Leone; Deanine Halliman; Nnenna Ihekoromadu; Matthew Feinsod

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1481. doi:

ARVO Annual Meeting Abstract June 2021

Visual function improvements with BIIB112 (NSR-RPGR) in X-linked retinitis pigmentosa: XIRIUS (dose-expansion) and XOLARIS (natural disease progression) studies

Robert E MacLaren; Byron L Lam; Andrew J Lotery; Paulo Eduardo Stanga; Assad Jalil; Mark E Pennesi; David G Birch; Christine Kay; Jiajun Liu; Eileen Liao; Lenore von Krusenstiern

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1479. doi:

1 2 3 4 5

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Filters

Specify Date Range

Commercially available, unmodified Octopus perimeters can characterize rod-photoreceptor function in two-color dark-adapted perimetry

Findings on visual photosensitivity in two phase 1/2 clinical trials of subretinal gene therapy with AGTC-401 and AGTC-402 for CNGB3 and CNGA3 achromatopsia

Characterizing the refractive error during the first 2 decades of life in patients with congenital stationary night blindness

Characterization of refractive error progression in patients with blue cone monochromacy

Exploratory Safety Profile of EDIT-101, a First-in-Human in vivo CRISPR Gene Editing Therapy for CEP290 -related Retinal Degeneration

Interim Safety Results in Two Phase 1/2 Open-label, Dose-escalation Clinical Trials of Subretinal Gene Therapy with AGTC-401 (rAAV2tYF-PR1.7-hCNGB3) and AGTC-402 (rAAV2tYF-PR1.7-hCNGA3) in Subjects with Achromatopsia (ACHM)

18 Month Analysis of Macular Structure using Optical Coherence Tomography (OCT) from a Phase 1/2 Clinical Study of Subretinal Gene Therapy Drug AGTC-501 for X-Linked Retinitis Pigmentosa

Visual acuity and full-field stimulus thresholds (FST) over 2 years in the RUSH2A study: annual rates of change from mixed effects modeling

The RUSH2A Study: Dark-Adapted Visual Fields in Patients With Retinal Degeneration Associated With Biallelic Variants in the USH2A Gene

Effect of Pharmacological Pupil Dilation on Dark-Adapted Perimetric Sensitivity in Healthy Subjects Using an Octopus 900 Perimeter

Characterization of the Spectrum of Ophthalmic Changes in Patients With Alagille Syndrome

NIGHT study: natural progression of choroideremia

Effect of pupil dilation on dark adapted perimetry using an Octopus 900 perimeter

Patient-reported visual functioning in persons with bi-allelic USH2A variants

Twelve-month Findings from Two Phase 1/2 Clinical Studies of Subretinal Gene Therapy Drugs for Achromatopsia

Treatment outcomes in 11 patients with RPE65- retinopathy receiving voritegene neparvovec-rzyl

Dark-adapted visual fields (DAVF) in patients with two disease-causing variants in USH2A

Phenotypic and genotypic spectrum of HGSNAT-related retinopathy

Six Month Findings from a Phase 1/2 Clinical Study of Subretinal Gene Therapy Drug AGTC-501 for X-Linked Retinitis Pigmentosa Show Clinically Meaningful Improvement in Macular Sensitivity

Visual function improvements with BIIB112 (NSR-RPGR) in X-linked retinitis pigmentosa: XIRIUS (dose-expansion) and XOLARIS (natural disease progression) studies

To View More...

You must be signed into an individual account to use this feature.